Core Viewpoint - Wohuah Pharmaceutical has reported strong financial performance for 2025, achieving significant growth in both revenue and net profit, demonstrating resilience and profitability in a challenging pharmaceutical industry environment [1][5]. Financial Performance - The company achieved a revenue of 817 million yuan, representing a year-on-year increase of 6.96% - The net profit attributable to shareholders reached 95.71 million yuan, with a remarkable year-on-year growth of 162.93%, marking the highest increase in nearly a decade - Operating cash flow increased by 40.45% year-on-year, and the company maintained a zero-interest-bearing debt structure, indicating strong internal cash generation capabilities [1][2]. Profit Distribution - The company continues its prudent dividend policy, proposing a cash dividend of 1.46 yuan per 10 shares, totaling 84.27 million yuan, reflecting its commitment to shareholder returns - Product quality control has shown significant results, with a 100% first-pass qualification rate and market inspection qualification rate for products in 2025 [2]. Product and Market Strategy - Wohuah Pharmaceutical has established a robust product matrix centered around four exclusive medical insurance pillar products, with 161 drug approval numbers, including 15 exclusive products and 93 products included in the national medical insurance catalog [2][3]. - The company has developed a comprehensive marketing system covering hospitals, retail pharmacies, grassroots medical institutions, and e-commerce platforms, achieving a dual-driven model of "in-hospital + out-of-hospital" [3][4]. Future Outlook - For 2026, the company plans to maintain strategic focus on traditional Chinese medicine R&D, production, and sales, while deepening its product cluster strategy - The company aims to optimize its academic promotion strategy for its leading product and expand its out-of-hospital market scale, exploring partnerships for "treatment solution" marketing models - Continued investment in R&D for 12 ongoing projects is planned, with a focus on integrating leading products into more clinical guidelines and medical insurance catalogs [4][5].

● 本报记者张鹏飞 1月19日晚间，沃华医药（002107）披露2025年年度报告，成为A股首家交出年度"答卷"的上市公司。 在医药行业政策深化调整、成本压力上升的背景下，沃华医药凭借产品集群优势、全终端营销布局与精 细化运营，实现营收与净利润双增长，归母净利润同比增幅高达162.93%，增幅创近10年以来新高，展 现出强劲的发展韧性与盈利弹性。 净利增速翻倍财务结构稳健 年报数据显示，2025年公司实现营业收入8.17亿元，同比增长6.96%；归属于上市公司股东的净利润 9571.53万元，同比增长162.93%，净利润增速显著高于营收增速，凸显盈利能力的结构性提升。值得关 注的是，公司经营质量持续优化，报告期内经营活动产生的现金流量净额同比增长40.45%，资产负债 结构保持高度稳健，有息负债持续为零，展现出强劲的内生造血能力。 在利润分配方面，公司延续稳健分红策略，在2025年中报每10股派发现金红利1.20元(含税)的基础上， 拟以2025年12月31日的总股本为基数，向全体股东每10股派发现金红利人民币1.46元(含税)，共计派发 现金红利8427万元(含税)，充分体现对股东的回报重视。此外，公司产 ...